Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease

Ansari, Azhar; Aziz, Ansar

doi:10.1111/apt.14687

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALT and fecal calprotectin were also decreased in patients [6]. There are several other studies that present with similar conclusions [4,[7][8][9][10][11].…”

Section: Am J Biomed Sci and Ressupporting

confidence: 75%

A Review of Azathioprine-Allopurinol Co-Treatment for Ulcerative Colitis

Nasir

2021

AJBSR

View full text Add to dashboard Cite

“…ALT and fecal calprotectin were also decreased in patients [6]. There are several other studies that present with similar conclusions [4,[7][8][9][10][11].…”

Section: Am J Biomed Sci and Ressupporting

confidence: 75%

A Review of Azathioprine-Allopurinol Co-Treatment for Ulcerative Colitis

Nasir

2021

AJBSR

View full text Add to dashboard Cite

“…We thank Drs. Ansari and Aziz for their insightful comments regarding the AAA study . We agree that the optimisation of small molecule therapy, by combining allopurinol with low doses of thiopurines, is a practical and cost‐effective alternative to escalation of therapy with the expensive biologic agents.…”

mentioning

confidence: 76%

Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply

Friedman

Sparrow

2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease

Vasudevan

Langenberg

2019

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Medication costs in inflammatory bowel disease (IBD) are now the principal driver of health care costs. Cost-effective strategies to optimize and rationalize treatment are therefore necessary. Methods A systematic review until April 30, 2018, was performed to identify economic evaluations of strategies to optimize infliximab, adalimumab, and immunomodulators for the treatment of IBD in adults. A qualitative synthesis of the identified studies was performed. Results Seventy articles were identified that met the inclusion criteria. Adalimumab seems cost-effective compared with infliximab as maintenance therapy for moderate to severe Crohn’s disease (CD). Infusion costs are a significant additional treatment cost with infliximab. However, other studies found biosimilar infliximab more cost-effective than alternative biologics in fistulizing and moderate-severe luminal CD—although the latter did not reach a willingness-to-pay threshold of <$50,000. In moderate-severe ulcerative colitis, infliximab seems more cost-effective than adalimumab. Multiple tailored approaches to treatment based on objective markers of disease activity or efficacy have been shown to be cost-effective in CD, including following secondary loss of response to anti-TNF therapy for postoperative recurrence and in escalating treatment. For immunomodulator treatment, both thiopurine methyltransferase (TPMT) testing before commencing thiopurines and thiopurine metabolite testing for dose optimization seem cost-effective. Conclusion In a win-win for patients and payers, several potential avenues to achieve cost-effectiveness—but also therapeutic optimization of anti-TNF therapies—were elucidated in this review with comparatively sparse data for immunomodulators. Optimizing immunomodulator and anti-tumor necrosis factor alpha therapy to achieve objective disease control seems to be cost-effective at conventional willingness-to-pay thresholds in a number of clinical settings.

show abstract

Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease

Abstract: Linked Content This article is linked to Friedman et al and Friedman and Sparrow papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14798.

Cited by 3 publications

References 5 publications

A Review of Azathioprine-Allopurinol Co-Treatment for Ulcerative Colitis

A Review of Azathioprine-Allopurinol Co-Treatment for Ulcerative Colitis

Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply

Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease

Contact Info

Product

Resources

About